Compare Amphastar Pharmaceuticals Inc (AMPH) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Enbridge Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Enbridge Inc trades at $51.81 (market cap $112.26B). The key difference: Enbridge Inc is far larger — about 129.9× Amphastar Pharmaceuticals Inc's market cap, and Enbridge Inc pays a 5.36% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ENB | |
|---|---|---|
Market Cap | $863.95M | $112.26B |
Sector | Health | Energy |
52-Week High | $30.81 | $58.04 |
52-Week Low | $16.87 | $45.23 |
Enterprise Value | $1.26B | $196.07B |
Dividend Yield | — | 5.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ENB trades at $51.28, down 0.81% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend track record with recent payouts of $0.97. Revenue grew to $65.19B in 2025, with a net income margin of 7.34%, though debt levels have increased.
Outlook is mixed; analyst consensus is evenly split between Buy and Hold, with a 48% Buy rating. Key opportunities include a $41B project backlog and consistent dividend growth, while risks involve high debt, regulatory challenges, and volatile cash flows. The stock's valuation appears reasonable with a P/E of 27.74.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
